← Back to All US Stocks

CUBT Stock Analysis - Curative Biotechnology Inc AI Rating

CUBT OTC Biological Products, (No Diagnostic Substances) FL CIK: 0001400271
Recently Updated • Analysis: Mar 23, 2026 • SEC Data: 2026-03-23
AI Rating
SELL
95% Confidence

📊 CUBT Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: SELL with 95% confidence

Investment Thesis

Curative Biotechnology Inc presents an uninvestable opportunity due to complete absence of financial data across all fundamental metrics. The company reports no revenue, no profitability data, and no operational cash flow, indicating either pre-revenue stage, operational distress, or severe reporting deficiencies that prevent fundamental analysis.

CUBT Strengths

  • -No strengths identified

CUBT Risks

  • ! Complete absence of financial reporting - no revenue, assets, or cash flow data available
  • ! No operational metrics to assess business viability or growth trajectory
  • ! Zero insider activity in last 90 days suggests potential management disengagement or inactive company status
  • ! OTC exchange listing compounds liquidity and transparency concerns
  • ! Insufficient data points (only 1 metric available) prevents meaningful fundamental analysis

Key Metrics to Watch

CUBT Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

CUBT Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

CUBT vs Healthcare Sector

How Curative Biotechnology Inc compares to Healthcare sector averages

Net Margin
CUBT 0.0%
vs
Sector Avg 12.0%
CUBT Sector
ROE
CUBT 0.0%
vs
Sector Avg 15.0%
CUBT Sector
Current Ratio
CUBT 0.0x
vs
Sector Avg 2.0x
CUBT Sector
Debt/Equity
CUBT 0.0x
vs
Sector Avg 0.6x
CUBT Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CUBT Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

CUBT Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

CUBT SEC Filings

Access official SEC EDGAR filings for Curative Biotechnology Inc (CIK: 0001400271)

📋 Recent SEC Filings

Date Form Document Action
Aug 1, 2025 S-1/A forms-1a.htm View →
May 6, 2024 S-1 forms-1.htm View →
Jan 25, 2023 S-1/A forms-1a.htm View →
Jan 13, 2023 S-1/A forms-1a.htm View →
Jan 9, 2023 S-1/A forms-1a.htm View →

Frequently Asked Questions about CUBT

What is the AI rating for CUBT?

Curative Biotechnology Inc (CUBT) has an AI rating of SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CUBT's key strengths?

.

What are the risks of investing in CUBT?

Complete absence of financial reporting - no revenue, assets, or cash flow data available. No operational metrics to assess business viability or growth trajectory.

What is CUBT's revenue and growth?

Curative Biotechnology Inc reported revenue of N/A.

Does CUBT pay dividends?

Curative Biotechnology Inc does not currently pay dividends.

Where can I find CUBT SEC filings?

Official SEC filings for Curative Biotechnology Inc (CIK: 0001400271) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CUBT's EPS?

Curative Biotechnology Inc has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2026-03-23 | Powered by Claude AI